recombinant von Willebrand factor

DRUG3 trials

Sponsors

Margaret Ragni, Nicoletta C Machin, University of Virginia

Conditions

Bleeding DisorderPostpartum HemorrhageVon Willebrand Diseases

Phase 1

Recombinant vWF Concentrate and ECMO

RecruitingNCT06118372

University of VirginiaBleeding Disorder

Start: 2024-10-03End: 2027-02-28Target: 12Updated: 2026-02-05

Phase 3

Minimize Menorrhagia in Women With Von Willebrand Disease

TerminatedNCT02606045

Margaret RagniVon Willebrand Diseases

Start: 2019-02-07End: 2022-08-30Updated: 2024-07-01

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

CompletedNCT04344860

Nicoletta C MachinPostpartum Hemorrhage, Von Willebrand Diseases

Start: 2021-06-04End: 2024-09-01Updated: 2025-10-31

Related Papers

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF.

2025-12-01

Impact of Tranexamic Acid Administration on Postpartum Hemorrhage in Women with Von Willebrand Disease Receiving Recombinant VWF at Delivery: The VWD Woman Trial

Blood2024-11-051 citations

Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.

2023-06-2624 citations

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Blood2022-11-15

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Blood2019-11-131 citations